Top Markets
Coin of the day
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Kedudukan dalam Saham #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Harga Saham
$0.71865803
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$80.86M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-5.48%
Negara
TW
Perdagangan GlycoNex Incorporation (4168)

Kategori

EPS untuk GlycoNex Incorporation (4168)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham GlycoNex Incorporation, EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk GlycoNex Incorporation dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH